Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smarter ventilator setting spare damaged lungs on ECMO?

NCT ID NCT07790133

Disease control Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Sep 02, 2026 · Updated 3 times

Summary

This pilot trial tests a ventilator strategy that targets a specific measure of lung stress, called mechanical power, in adults with severe ARDS who are on VV ECMO. The goal is to see if this approach is feasible and safe compared to standard ultra-low tidal volume ventilation. Researchers will check how well patients stick to the protocol and watch for complications like low oxygen or high carbon dioxide. If successful, this could lead to better, research-based ventilator settings for the sickest lung patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mechanical power targeted ventilation, a ventilator strategy that adjusts breathing settings to minimize lung damage
What this could lead to
If it works, this could point toward a safer, evidence-based way to set ventilators for ARDS patients on ECMO, potentially improving recovery and survival.
What could go wrong
This is a small pilot study with only 24 patients, so results may not apply broadly. The strategy might not be feasible or could cause complications like low oxygen or high carbon dioxide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. On VV ECMO for less than 24 hours at time of study consent 2. Severe ARDS as the primary etiology of respiratory failure defined by: * Acute onset: Within 1 week of known clinical insult * Bilateral infiltrates: Evidence of fluid/inflammation in both lungs on X-ray, CT, or US, not fully explained by cardiac failure or fluid overload * Origin of Edema: Respiratory failure not fully explained by cardiac failure or fluid overload * Oxygenation impairment (Severe): PaO2/FiO2 ≤ 100 mm HG (Partial pressure of arterial oxygen/Fraction of inspired oxygen) 3. Age 18 or greater Exclusion Criteria 1. Have received ECMO for \>24 hours 2. Are on VV ECMO but are not mechanically ventilated, or are planned not to have/not require invasive mechanical ventilation for \>24 hours 3. Patient is pregnant 4. Patient is a prisoner 5. Receiving VV ECMO as a bridge to transplant or history of lung transplant 6. History of pneumectomy or lobectomy 7. Age \< 18 8. Are on any hybrid configuration of ECMO including an arterial limb (i.e., VAV, VVA, VA, etc.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS (acute respiratory distress syndrome) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome Ventilator-Induced Lung Injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS (acute respiratory distress syndrome) VV ecmo

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.